The effect of Nano-curcumin supplementation on clinical symptoms and signs, length of hospital stays and inflammation level in moderate acute pancreatitis.

Phase 2

Conditions: Moderate Acute Pancreatitis.
Acute pancreatitis

Registration Number: IRCT20100524004010N33

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 42

Inclusion Criteria

Having desire to participate in the study
Age range of 18-75
Patients with a clinical diagnosis of moderate acute pancreatitis (specifically, a history of acute abdominal pain associated with a greater than threefold elevation of the serum amylase and/or computed tomographic evidence of acute pancreatitis) presenting within 72 hours of onset of pain.
Having the ability to intake soft gels orally

Exclusion Criteria

Pregnancy or breastfeeding
History of allergy to Curcumin
Acute exacerbation of chronic pancreatitis
Taking antioxidant supplements such as vitamin C, vitamin E or omega 3
Severe co-morbid illness (liver disease including Cirrhosis and Hepatitis, renal failure (Cl Cr <30))
Active gastrointestinal ulcers
Taking anticoagulants such as Heparin, Clopidogrel, Dipyridamole, Warfarin and Ticlopidine

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ength of hospital stay. Timepoint: Through study completion, an average of two weeks. Method of measurement: Counting the number of admission days in hospital based on medical records.;Serum C-reactive protein level. Timepoint: At the first and the end of the 2nd week of the study. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).

Secondary Outcome Measures